The stock of Adma Biologics Inc (ADMA) has gone down by -2.00% for the week, with a -13.26% drop in the past month and a 0.25% rise in the past quarter. The volatility ratio for the week is 4.67%, and the volatility levels for the past 30 days are 4.97% for ADMA. The simple moving average for the last 20 days is -7.58% for ADMA stock, with a simple moving average of 10.77% for the last 200 days.
Is It Worth Investing in Adma Biologics Inc (NASDAQ: ADMA) Right Now?
The price-to-earnings ratio for Adma Biologics Inc (NASDAQ: ADMA) is above average at 58.49x, Company’s 36-month beta value is 0.75.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ADMA is 228.50M, and currently, short sellers hold a 5.96% ratio of that floaft. The average trading volume of ADMA on January 22, 2025 was 3.00M shares.
ADMA) stock’s latest price update
Adma Biologics Inc (NASDAQ: ADMA)’s stock price has plunge by 0.87relation to previous closing price of 16.02. Nevertheless, the company has seen a -2.00% plunge in its stock price over the last five trading sessions. marketbeat.com reported 2025-01-20 that Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed’s first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at -15.40% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.64% of loss for the given period.
Volatility was left at 4.97%, however, over the last 30 days, the volatility rate increased by 4.67%, as shares sank -8.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.18% lower at present.
During the last 5 trading sessions, ADMA fell by -2.00%, which changed the moving average for the period of 200-days by +154.49% in comparison to the 20-day moving average, which settled at $17.48. In addition, Adma Biologics Inc saw -5.77% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from Tade Brad L., who sale 15,000 shares at the price of $21.15 back on Nov 22 ’24. After this action, Tade Brad L. now owns 199,433 shares of Adma Biologics Inc, valued at $317,250 using the latest closing price.
Grossman Adam S, the President and CEO of Adma Biologics Inc, sale 48,967 shares at $21.10 during a trade that took place back on Nov 22 ’24, which means that Grossman Adam S is holding 1,989,007 shares at $1,033,204 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.3 for the present operating margin
- 0.49 for the gross margin
The net margin for Adma Biologics Inc stands at 0.18. The total capital return value is set at 0.33. Equity return is now at value 35.55, with 18.42 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at 0.77. The debt to equity ratio resting at 0.48. The interest coverage ratio of the stock is 6.65.
Currently, EBITDA for the company is 5.12 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 10.04. The receivables turnover for the company is 7.63for trailing twelve months and the total asset turnover is 0.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.09.
Conclusion
In a nutshell, Adma Biologics Inc (ADMA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
